MDT

85.76

-0.01%↓

114.93

+1.35%↑

VEEV

174.59

-0.81%↓

HQY

82.54

+0.3%↑

PHR.US

8.36

+0.97%↑

MDT

85.76

-0.01%↓

114.93

+1.35%↑

VEEV

174.59

-0.81%↓

HQY

82.54

+0.3%↑

PHR.US

8.36

+0.97%↑

MDT

85.76

-0.01%↓

114.93

+1.35%↑

VEEV

174.59

-0.81%↓

HQY

82.54

+0.3%↑

PHR.US

8.36

+0.97%↑

MDT

85.76

-0.01%↓

114.93

+1.35%↑

VEEV

174.59

-0.81%↓

HQY

82.54

+0.3%↑

PHR.US

8.36

+0.97%↑

MDT

85.76

-0.01%↓

114.93

+1.35%↑

VEEV

174.59

-0.81%↓

HQY

82.54

+0.3%↑

PHR.US

8.36

+0.97%↑

Home・Elenco Azioni・Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc

Aperta

1.72 -1.15

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.6600000000000001

Massimo

1.8199999999999998

Metriche Chiave
By Trading Economics
Entrata	23T 23T
Dipendenti	8
EBITDA	1.1T 1.1T

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+227.38% upside

Dividendi
By Dow Jones
Utili prossimi	12 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-199M 101M
Apertura precedente	2.87
Chiusura precedente	1.72

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

1.9 / 2.65 Supporto e resistenza

Aldeyra Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 mar 2026, 13:34 UTC

I principali Market Mover

Aldeyra Therapeutics Shares Fall as Drug Rejected by Regulator on Efficacy Concerns

16 dic 2025, 11:43 UTC

I principali Market Mover

Aldeyra Shares Fall Premarket After FDA Extends Reproxalap Review

3 apr 2025, 22:40 UTC

I principali Market Mover

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

Confronto tra pari

Modifica del prezzo

Aldeyra Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

227.38% in crescita

Previsioni per 12 mesi

Media 5.5 USD 227.38%

Alto 9 USD

Basso 2 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Aldeyra Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 2 che hanno fornito valutazioni azionarie a Aldeyra Therapeutics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

1.9 / 2.65Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.